Lindi Biotechnology

Lindis Biotech is a clinical-stage biopharmaceutical company based in Munich, Germany, dedicated to developing a new class of T-cell engaging bispecific antibodies known as Triomab. The company's proprietary platform produces trifunctional antibodies that simultaneously target tumor antigens, T-cells, and accessory cells like macrophages and NK cells to trigger a comprehensive immune response. Its lead candidate, catumaxomab, is being evaluated in Phase 2 clinical trials for the treatment of non-muscle-invasive bladder cancer (NMIBC). By leveraging its unique antibody architecture, Lindis Biotech aims to transform malignant cancers into manageable or curable diseases through targeted immunotherapy.